FLXN Flexion Therapeutics Inc.

Flexion Therapeutics Announces Pricing of Public Offering of Common Stock

Flexion Therapeutics Announces Pricing of Public Offering of Common Stock

BURLINGTON, Mass., May 21, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the pricing of an underwritten public offering of 9,230,770 shares of its common stock at a price to the public of $9.75 per share. The gross proceeds from this offering are expected to be approximately $90.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Flexion. The offering is expected to close on or about May 26, 2020, subject to customary closing conditions. Flexion has also granted the underwriters a 30-day option to purchase up to 1,384,615 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Goldman Sachs & Co. LLC and Credit Suisse are acting as joint book-running managers for the offering. RBC Capital Markets is acting as senior manager and Raymond James and Needham & Company are acting as co-managers for the offering.

The shares of common stock described above are being offered pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (SEC). A final prospectus supplement relating to the offering will be filed with the SEC and available for free on the SEC's website at Copies of the final prospectus supplement and the accompanying prospectus relating to the offering, when available, may also be obtained from: Goldman Sachs & Co. LLC by mail at 200 West Street, New York, NY 10282, Attention: Prospectus Department, by telephone at (866) 471-2526, or by email at l.gs.com; or Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, Eleven Madison Avenue, 3rd Floor, New York, NY 10010, by telephone at (800) 221-1037, or by email at  .

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Flexion Therapeutics

Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The company's core values are focus, ingenuity, tenacity, transparency and fun.

Forward-Looking Statements



This press release contains forward-looking statements that are based on our current expectations and beliefs. Statements in this press release regarding matters that are not historical facts, including, but not limited to, statements relating to expectations regarding the completion and timing of the public offering, are forward-looking statements. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, risks associated with market conditions and the satisfaction of customary closing conditions related to the offering, as well as other risks and uncertainties described in our filings with the SEC, including under the heading "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 and subsequent filings with the SEC. There can be no assurance that we will be able to complete the public offering on the anticipated terms, or at all. The forward-looking statements in this press release speak only as of the date of this press release, and we undertake no obligation to update or revise any of the statements. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.

Contact:

Scott Young

Vice President, Corporate Communications & Investor Relations

T: 781-305-7194

Julie Downs

Associate Director, Corporate Communications & Investor Relations

T: 781-305-7137

EN
21/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Flexion Therapeutics Inc.

 PRESS RELEASE

Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding L...

Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management -- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway -- -- Further enhances topline revenue growth; provides attractive potential synergies and expected to be accretive to full-year 2022 earnings and significantly accretive thereafter -- -- Pacira to host conference call today at 8:30 AM ET -- TAMPA, Fla. and BURLINGTON, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- (Nas...

 PRESS RELEASE

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Ru...

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BURLINGTON, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to three new employees consisting of 6,315 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of October 1, 2021. The restricted stock units were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted sto...

 PRESS RELEASE

Flexion Therapeutics to Present at the H.C. Wainwright 23rd Annual Glo...

Flexion Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference BURLINGTON, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in a virtual analyst-led fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021. The presentation will be available through an on-demand webcast beginning at 7 a.m. ET on September 13, 2021, and will be accessible on the Flexion website at . Ab...

 PRESS RELEASE

Flexion Therapeutics to Present at the Wells Fargo 2021 Virtual Health...

Flexion Therapeutics to Present at the Wells Fargo 2021 Virtual Healthcare Conference BURLINGTON, Mass., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Wells Fargo 2021 Virtual Healthcare Conference. The virtual fireside chat is scheduled to begin at 4:35 p.m. ET on Thursday, September 9, 2021. To access the live webcast of the presentation, please visit the Flexion website at . About Flexion TherapeuticsFlexion Therapeut...

 PRESS RELEASE

Flexion Therapeutics Announces Inclusion of ZILRETTA® in American Acad...

Flexion Therapeutics Announces Inclusion of ZILRETTA® in American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines for the Management of Osteoarthritis of the Knee AAOS finds that ZILRETTA (triamcinolone acetonide extended-release injectable suspension) can improve patient outcomes over immediate-release corticosteroids BURLINGTON, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that the American Academy of Orthopaedic Surgeons (AAOS) included ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in its...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch